Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213303089> ?p ?o ?g. }
- W4213303089 endingPage "424" @default.
- W4213303089 startingPage "408" @default.
- W4213303089 abstract "Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hepatitis B virus (HBV) antigen production and viral replication. By reducing viral antigens, host immune reconstitution against HBV may also be attained. Phase I/II trials on siRNAs have demonstrated them to be safe and well-tolerated. siRNA is effective when given in monthly doses with different total number of doses according to different trial design, and can lead to sustainable dose-dependent mean HBsAg reduction by 2-2.5 log. Incidences of HBsAg seroclearance after siRNA therapy have also been reported. ASOs have also been studied in early phase trials, and a phase Ib study using frequent dosing regimen within 4 weeks could achieve similar HBsAg reduction of 2 log from baseline. Given the established efficacy and safety of nucleos(t) ide analogues (NAs), future RNAi regimens will likely include NA backbone. While the current evidence on RNAi appears promising, it remains undetermined whether the potent HBsAg reduction by RNAi can result in a high rate of HBsAg seroclearance with durability. Data on RNAi from phase IIb/III trials are keenly anticipated." @default.
- W4213303089 created "2022-02-24" @default.
- W4213303089 creator A5025402851 @default.
- W4213303089 creator A5060179994 @default.
- W4213303089 creator A5083700089 @default.
- W4213303089 date "2022-07-01" @default.
- W4213303089 modified "2023-09-30" @default.
- W4213303089 title "RNA interference as a novel treatment strategy for chronic hepatitis B infection" @default.
- W4213303089 cites W1647075334 @default.
- W4213303089 cites W1942432888 @default.
- W4213303089 cites W1966543080 @default.
- W4213303089 cites W1968503956 @default.
- W4213303089 cites W1983251878 @default.
- W4213303089 cites W1984085632 @default.
- W4213303089 cites W1988500121 @default.
- W4213303089 cites W1996830006 @default.
- W4213303089 cites W1999477205 @default.
- W4213303089 cites W2006622006 @default.
- W4213303089 cites W2019631541 @default.
- W4213303089 cites W2020368715 @default.
- W4213303089 cites W2022955650 @default.
- W4213303089 cites W2023843484 @default.
- W4213303089 cites W2027954222 @default.
- W4213303089 cites W2032945651 @default.
- W4213303089 cites W2033927435 @default.
- W4213303089 cites W2037067282 @default.
- W4213303089 cites W2037140037 @default.
- W4213303089 cites W2037269568 @default.
- W4213303089 cites W2040234712 @default.
- W4213303089 cites W2048056516 @default.
- W4213303089 cites W2051891056 @default.
- W4213303089 cites W2053103314 @default.
- W4213303089 cites W2076361525 @default.
- W4213303089 cites W2084152099 @default.
- W4213303089 cites W2095509700 @default.
- W4213303089 cites W2102110918 @default.
- W4213303089 cites W2102216644 @default.
- W4213303089 cites W2102694589 @default.
- W4213303089 cites W2103805774 @default.
- W4213303089 cites W2107762071 @default.
- W4213303089 cites W2117698690 @default.
- W4213303089 cites W2125684318 @default.
- W4213303089 cites W2125944823 @default.
- W4213303089 cites W2136447541 @default.
- W4213303089 cites W2143313350 @default.
- W4213303089 cites W2149221950 @default.
- W4213303089 cites W2158110042 @default.
- W4213303089 cites W2267571233 @default.
- W4213303089 cites W2334983393 @default.
- W4213303089 cites W2338215546 @default.
- W4213303089 cites W2396178441 @default.
- W4213303089 cites W2463090831 @default.
- W4213303089 cites W2531015819 @default.
- W4213303089 cites W2591653764 @default.
- W4213303089 cites W2612651481 @default.
- W4213303089 cites W2624035866 @default.
- W4213303089 cites W2630192492 @default.
- W4213303089 cites W2737645474 @default.
- W4213303089 cites W2757654367 @default.
- W4213303089 cites W2785700629 @default.
- W4213303089 cites W2785853755 @default.
- W4213303089 cites W2801011399 @default.
- W4213303089 cites W2801666689 @default.
- W4213303089 cites W2803566305 @default.
- W4213303089 cites W2810909862 @default.
- W4213303089 cites W2892030934 @default.
- W4213303089 cites W2896802137 @default.
- W4213303089 cites W2900235043 @default.
- W4213303089 cites W2900781853 @default.
- W4213303089 cites W2920438880 @default.
- W4213303089 cites W2924326751 @default.
- W4213303089 cites W2930517794 @default.
- W4213303089 cites W2962219096 @default.
- W4213303089 cites W2981927057 @default.
- W4213303089 cites W2983910901 @default.
- W4213303089 cites W3003378907 @default.
- W4213303089 cites W3010530314 @default.
- W4213303089 cites W3017264315 @default.
- W4213303089 cites W3035585198 @default.
- W4213303089 cites W3036807836 @default.
- W4213303089 cites W3037517625 @default.
- W4213303089 cites W3047675473 @default.
- W4213303089 cites W3133741463 @default.
- W4213303089 cites W3165162313 @default.
- W4213303089 cites W3174293101 @default.
- W4213303089 cites W3197061720 @default.
- W4213303089 cites W3202066002 @default.
- W4213303089 cites W3207599520 @default.
- W4213303089 cites W4200147324 @default.
- W4213303089 cites W4231473229 @default.
- W4213303089 cites W4254038279 @default.
- W4213303089 doi "https://doi.org/10.3350/cmh.2022.0012" @default.
- W4213303089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35172540" @default.
- W4213303089 hasPublicationYear "2022" @default.
- W4213303089 type Work @default.
- W4213303089 citedByCount "20" @default.
- W4213303089 countsByYear W42133030892022 @default.
- W4213303089 countsByYear W42133030892023 @default.